

Resource Summary Report

Generated by [RRID](#) on Sep 9, 2026

Anti-Human DR5 (Drozitumab) - Fc Muted™ Biotin

RRID:AB_2894002

Type: Antibody

Proper Citation

Leinco Technologies Cat# LT706, RRID:AB_2894002

Antibody Information

URL: http://antibodyregistry.org/AB_2894002

Proper Citation: Leinco Technologies Cat# LT706, RRID:AB_2894002

Target Antigen: DR5

Host Organism: human

Clonality: recombinant monoclonal

Comments: Applications: ELISA, FA, FC

Info: This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Drozitumab. Clone PRO95780 recognizes human death receptor 5 (DR5). This product is for research use only.

Antibody Name: Anti-Human DR5 (Drozitumab) - Fc Muted™ Biotin

Description: This recombinant monoclonal targets DR5

Target Organism: human

Clone ID: clone: PRO95780

Antibody ID: AB_2894002

Vendor: Leinco Technologies

Catalog Number: LT706

Record Creation Time: 20231110T031706+0000

Record Last Update: 20260829T052854+0000

Ratings and Alerts

No rating or validation information has been found for Anti-Human DR5 (Drozitumab) - Fc Muted™ Biotin.

No alerts have been found for Anti-Human DR5 (Drozitumab) - Fc Muted™ Biotin.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Wang G, et al. (2026) VGLL4 promotes hepatocellular carcinoma progression via the Wnt/ β -catenin pathway. Tissue & cell, 100, 103391.